Century Extrusions allots 3 crore partly paid equity shares on rights basis
Key highlights
- Allotment approved on October 22, 2026, during Rights Issue Committee meeting
- 3,00,00,000 partly paid shares of ₹1 face value each allotted on rights basis
- Issue price fixed at ₹15 per share, including ₹14 premium per share
Why it's rated notable: The allotment of 3,00,00,000 partly paid rights shares at ₹15 each, about ₹45 crore implied, is about 24% of the stated ₹186 crore market value, which sets the level at medium.
Original filing
Announcement under Regulation 30 (LODR)-Allotment
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other fundraise / allotment filings this fortnight
- Clean Max Enviro: Q2 results, NCDs up to Rs 3,000 crore approved, IFSC subsidiary planned
- Lloyds Metals and Energy Limited approves Q2 results, investment, and fundraising plans
- Lloyds Metals approves Q2 results, ₹625 crore TEIL investment and USD 300 million debt
- Mena Mani Industries approves Sept 2026 results, hotel venture and software expansion
- Sat Kartar Life Limited receives NSE approval for 5,50,000 convertible warrants issue
- CL Educate Limited approves ₹140 Cr fund raise and reports Q2 FY27 financials
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.